Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2014 - 201922020 - 20212

Settings

Subject: search.filters.subject.Cardiovascular diseases

Search Results

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Effects of Infliximab Treatment in Terms of Cardiovascular Risk and Insulin Resistance in Ankylosing Spondylitis Patients
    (2014) Bozkirli, Emine Duygu Ersozlu; Bozkirli, Emre; Yucel, Ahmet Eftal; https://orcid.org/0000-0002-4860-9072; 24252046; E-9887-2014
    Objective. To assess the effects of infliximab treatment on insulin sensitivity and cardiovascular risk factors in patients with ankylosing spondylitis (AS). Methods. In this prospective study, 30 consecutive AS patients (23 men and 7 women) fulfilling the modified 1984 New York criteria for AS were investigated. All patients were treated with intravenous infliximab. A complete biochemical profile and assesments were obtained before and after 12 weeks of infliximab therapy. The Homoeostasis Model Assessment of Insulin Resistance Index (HOMA-IR) was used to measure insulin resistance (IR). Framingham equation was used to assess cardiovascular risk factors. Results. After 12 weeks of infliximab treatment, there was no statistically significant difference in fasting insulin, HOMA-IR, lipid parameters, body-mass index, waist circumference and waist hip ratio, whereas fasting glucose levels (p = 0.001), triglycerides/high-density lipoprotein (HDL) ratio (p = 0.043) and total cholesterol/HDL (p = 0.041) ratio increased significantly from baseline. A significant decrease was observed for both systolic blood pressures (p < 0.001) and diastolic blood pressures (p = 0.003) in the 12th-week visit. A significant decrease was also found in terms of Framingham risk scores (p = 0.028) after treatment. Conclusions. Study results suggest that infliximab treatment may reduce cardiovascular risk and blood pressures without changing IR.
  • No Thumbnail Available
    Item
    Plasma GDF-15 Levels and Their Association with Hormonal and Metabolic Status in Women with Polycystic Ovary Syndrome Aged 25-35
    (2014) Berberoglu, Z.; Aktas, A.; Fidan, Y.; Yazici, A. Canan; Aral, Y.; https://orcid.org/0000-0002-3132-242X; 24736483; AAS-6810-2021
    Aim. We aimed to determine plasma levels of growth differentiation factor (GDF)-15 and their possible association with hormonal and metabolic status, as well as echocardiographic profiles and carotid artery intima-media thickness (CAIMT) measurements in patients with polycystic ovary syndrome (PCOS). Methods. Forty-two obese PCOS women aged 25-35 years, 23 women with idiopathic hirsutism and 20 healthy controls matched for age and body mass index were enrolled. Anthropometric, metabolic and hormonal patterns, plasma GDF-15 concentrations, CAIMT, and conventional echocardiographic parameters were measured. Results. Metabolic/lipid profiles as well as GDF-15 levels were similar across the three groups. CAIMT tended to be higher in PCOS group but did not reach statistical significance. No between-group differences were found in the conventional echocardiographic parameters. Analysis of PCOS patients showed a significant correlation of GDF-15 concentrations with age and homeostasis model assessment (HOMA) index (r=0.319, P<0.05, and r=0.312, P<0.05, respectively). In multiple linear regression analyses, GDF-15 was significantly associated with age (r(2)=0.102, P<0.05), and HOMA index (r(2)=0.10, P<0.05). Conclusion. Plasma GDF-15 levels, CAIMT and conventional echocardiographic parameters in obese subjects with PCOS (25-35 yrs old) were comparable to those in either subjects with idiopathic hirsutism or healthy controls with similar anthropometric and metabolic profiles, suggesting that PCOS alone could not impart an early and higher risk independent of associated risk factors. GDF-15 might provide a link between future diabetes and cardiovascular risk in PCOS women.
  • No Thumbnail Available
    Item
    Impact of the Novel Coronavirus Disease 2019 (COVID-19) Pandemic on Cardiac Emergencies and Future Perspectives in Turkey
    (2021) Coner, Ali; Kayipmaz, Afin Emre; Celikel, Elif; 0000-0002-5711-8873; ABD-7321-2021
    SARS-CoV-2-associated COVID-19 pandemic has affected the daily life of people across the world in 2020. Data about the course of viral involvement continues to be accumulated. COVID-19 is a multi-systemic disease, and the clinical presentations and possible complications may vary widely in different patient groups. The cardiovascular system is a primary target of COVID-19, and direct or indirect effects of viral involvement are observed. In addition to the direct effects of viral involvement on the cardiovascular system, decrement in acute cardiac emergencies has been experienced in many cardiology clinics in Turkey during the pandemic. Moreover, there may be a possible increase in out-of-hospital cardiac arrests in the near future. In this narrative review, we aimed to discuss the cardiac manifestations of COVID-19, the possible drug interactions related to the drugs used for COVID-19 management, and the effect of the pandemic on cardiac emergencies. We believe that understanding the natural mechanism of cardiac involvement of SARS-CoV-2 and emphasizing the data about out-of-hospital arrests will help clinicians effectively deal with the preventable cardiovascular causes of death in the forthcoming waves of COVID-19.
  • No Thumbnail Available
    Item
    Sodium-glucose cotransporter-2 inhibitors in heart failure patients: an appraisal of recent cardiovascular outcome trials
    (2020) Kocyigit, Duygu; Kocyigit, Alime S.; Hussain, Muzna; 33059407
    Although initially introduced as a novel oral glucose-lowering agent class, cumulative evidence from randomized controlled trials (RCTs) have led sodium-glucose cotransporter-2 inhibitors (SGLT2i) to become a component of primary and secondary prevention from atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus (T2DM). Dapagliflozin, one of the agents of this class, was investigated in 2019 in patients with heart failure (HF) independent of being diagnosed with T2DM at baseline. Since then, many other studies are being undertaken in this class of drugs. Herein, we aimed to review the RCTs, their subgroup and post-hoc analyses that examined the effects of SGLT2i on cardiovascular outcomes (including HF-related outcomes) in patients diagnosed with HF that were published until June 2020. We also summarized the ongoing trials that aim to assess the impact of SGLT2i on cardiovascular outcomes in patients with HF and listed available guideline recommendations regarding the use of SGLT2i for cardiovascular disease management.